Skip to main content
Home

Main navigation

  • Company
    • Company profile
    • Leadership team
    • Scientific Advisory Board
    • Board of Directors
  • R&D Programs
    • Pipeline overview
    • DIACC1010
    • DIACC2010/DIACC2020
    • DIACC3010
  • Partnering
  • Media
    • Media hub
    • All press releases
    • All events
    • Media center
  • Careers
  • Contact
  • Search
  • en
  • fr

Latest news

Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development

June 24, 2022

Diaccurate appoints Laurence Riot Lamotte as Chief Financial Officer

February 8, 2022

Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany

September 8, 2021
See all press releases
  1. Home
  2. Media

Selected media

BioSpace

Diaccurate Adds Merck PAM Inhibitor to Oncology/Immunology Pipeline

September 9, 2021
EndPoints

Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway

September 8, 2021
BioWorld

Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out

August 12, 2021

Media contact details

MC Services (US & EU)

Anne Hennecke
+49 211 529252 22

Simone Neeten
+49 211 52925217

diaccurate@mc-services.eu

ATCG Partners (France)

Marie Puvieux
+33 (0)9 52 78 85 08

diaccurate@atcg-partners.com

Location

Headquarters: 104 Bd de Sébastopol, 75003 Paris

Lab: 60 avenue André Roussin, 13016 Marseille

  33 (0)1 78 96 41 70

Stay in touch

Subscribe to our newsletter

Contact us

Follow us

   

Footer

  • Legal info
  • Privacy notice
  • Cookies notice